Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]

M Fassnacht; G Assie; E Baudin; G Eisenhofer; C de la Fouchardiere; H R Haak; R de Krijger; F Porpiglia; M Terzolo; A Berruti; ESMO Guidelines Committee

doi:10.1016/j.annonc.2022.12.006

Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]

M Fassnacht^*
, G Assie
, E Baudin
, G Eisenhofer
, C de la Fouchardiere
, H R Haak
, R de Krijger
, F Porpiglia
, M Terzolo
, A Berruti
, ESMO Guidelines Committee

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum › Academic

Abstract

The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	631-631
Number of pages	1
Journal	Annals of Oncology
Volume	34
Issue number	7
Early online date	21 Dec 2022
DOIs	https://doi.org/10.1016/j.annonc.2022.12.006
Publication status	Published - Jul 2023

Access to Document

10.1016/j.annonc.2022.12.006Licence: Free access - publisher

Fingerprint

Dive into the research topics of 'Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]'. Together they form a unique fingerprint.

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., Berruti, A. & ESMO Guidelines Committee, Nov 2020, In: Annals of Oncology. 31, 11, p. 1476-1490 15 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., Fouchardiere, C. D. L., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., Berruti, A., & ESMO Guidelines Committee (2023). Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]. Annals of Oncology, 34(7), 631-631. https://doi.org/10.1016/j.annonc.2022.12.006

@article{ef7c5d5f201c48d983c74e4343bb97b2,

title = "Corrigendum to {"}Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up{"}: Annals of Oncology volume 31 (2020) 1476-1490]",

abstract = "The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.",

author = "M Fassnacht and G Assie and E Baudin and G Eisenhofer and Fouchardiere, \{C de la\} and Haak, \{H R\} and \{de Krijger\}, R and F Porpiglia and M Terzolo and A Berruti and \{ESMO Guidelines Committee\}",

note = "Publisher Copyright: {\textcopyright} 2022 European Society for Medical Oncology",

year = "2023",

month = jul,

doi = "10.1016/j.annonc.2022.12.006",

language = "English",

volume = "34",

pages = "631--631",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "7",

}

Fassnacht, M, Assie, G, Baudin, E, Eisenhofer, G, Fouchardiere, CDL, Haak, HR, de Krijger, R, Porpiglia, F, Terzolo, M, Berruti, A & ESMO Guidelines Committee 2023, 'Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]', Annals of Oncology, vol. 34, no. 7, pp. 631-631. https://doi.org/10.1016/j.annonc.2022.12.006

Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]. / Fassnacht, M; Assie, G; Baudin, E et al.
In: Annals of Oncology, Vol. 34, No. 7, 07.2023, p. 631-631.

Research output: Contribution to journal › Erratum / corrigendum › Academic

TY - JOUR

T1 - Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up"

T2 - Annals of Oncology volume 31 (2020) 1476-1490]

AU - Fassnacht, M

AU - Assie, G

AU - Baudin, E

AU - Eisenhofer, G

AU - Fouchardiere, C de la

AU - Haak, H R

AU - de Krijger, R

AU - Porpiglia, F

AU - Terzolo, M

AU - Berruti, A

AU - ESMO Guidelines Committee

PY - 2023/7

Y1 - 2023/7

N2 - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.

U2 - 10.1016/j.annonc.2022.12.006

DO - 10.1016/j.annonc.2022.12.006

M3 - Erratum / corrigendum

C2 - 36564283

SN - 0923-7534

VL - 34

SP - 631

EP - 631

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Fassnacht M, Assie G, Baudin E, Eisenhofer G, Fouchardiere CDL, Haak HR et al. Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology volume 31 (2020) 1476-1490]. Annals of Oncology. 2023 Jul;34(7):631-631. Epub 2022 Dec 21. doi: 10.1016/j.annonc.2022.12.006